A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

NCT ID: NCT00383019

Last Updated: 2021-09-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-14

Study Completion Date

2007-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between Xalacom and Xalatan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xalatan

Group Type EXPERIMENTAL

Xalatan

Intervention Type DRUG

latanoprost 0.005%, one rop once daily in evening

Xalacom

Group Type EXPERIMENTAL

Xalacom

Intervention Type DRUG

latanoprost 0.005% adn timolol 0.5%, one drop, once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xalatan

latanoprost 0.005%, one rop once daily in evening

Intervention Type DRUG

Xalacom

latanoprost 0.005% adn timolol 0.5%, one drop, once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4 weeks or more.

Exclusion Criteria

* History of no-response to timolol
* History of trabeculectomy
* History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nomura Eye Clinic

Ichinomiya, Aichi-ken, Japan

Site Status

Matsusura Eye Clinic

Ichinomiya, Aichi-ken, Japan

Site Status

Yasuma Eye Clinic

Nagoya, Aichi-ken, Japan

Site Status

TANABE Eye Clinic

Nagoya, Aichi-ken, Japan

Site Status

Suzuki Eye Clinic

Nagoya, Aichi-ken, Japan

Site Status

Mitsuhashi Eye Clinic

Narashino, Chiba, Japan

Site Status

Ohtsuka Eye Clinic

Sapporo, Hokkaido, Japan

Site Status

Sasamoto Eye Clinic

Sapporo, Hokkaido, Japan

Site Status

Ohyachi Kyouritsu Eye Clinic

Sapporo, Hokkaido, Japan

Site Status

Kaimeido Eye Clinic

Sapporo, Hokkaido, Japan

Site Status

Kobe University Hospital

Koube, Hyōgo, Japan

Site Status

Kanazawa university hospital

Kanazawa, Ishikawa-ken, Japan

Site Status

Lumine Hatano Eye Clinic

Fujisawa, Kanagawa, Japan

Site Status

Tanino clinic

Kamakura, Kanagawa, Japan

Site Status

Aoki eye clinic

Sagamihara, Kanagawa, Japan

Site Status

Kikuna Yuda Eye Clinic

Yokohama, Kanagawa, Japan

Site Status

Fujita Eye Clinic

Sapporo, Kokkaido, Japan

Site Status

Chihara Eye Clinic

Uji, Kyoto, Japan

Site Status

Miyata Eye Hospital

Miyakonojō, Miyazaki, Japan

Site Status

Hayashi Eye Clinic

Kumagaya, Saitama, Japan

Site Status

Hiraoka Eye Clinic

Tokorozawa, Saitama, Japan

Site Status

Hanasaki Eye Clinic

Fuji, Shizuoka, Japan

Site Status

Nakajima Eye Clinic

Fuji, Shizuoka, Japan

Site Status

Yoshimura Eye & Internal Medical Clinic

Mishima, Shizuoka, Japan

Site Status

Muramatsu Ganka Clinic

Susono, Shizuoka, Japan

Site Status

The University of Tokyo Hospital

Bunkyo-ku, Tokyo, Japan

Site Status

Tokyo Metropolitan Police Hospital

Chiyoda City, Tokyo, Japan

Site Status

Ochanomizu Inoue Eye Clinic

Chiyoda-ku, Tokyo, Japan

Site Status

Keio Hachioji Matsumoto Eye Clinic

Hachiōji, Tokyo, Japan

Site Status

Manabe Clinic

Hamura, Tokyo, Japan

Site Status

Tokyo Sugita Eye Center

Katsushika-ku, Tokyo, Japan

Site Status

Kiyosenomori Hospital

Kiyose, Tokyo, Japan

Site Status

Miyazaki Eye Clinic

Koto-ku, Tokyo, Japan

Site Status

Takase Ganka Tairamachi Clinic

Meguro City, Tokyo, Japan

Site Status

Ohashi Eye Clinic

Meguro-ku, Tokyo, Japan

Site Status

Kunitoshi Eye Clinic

Musashino, Tokyo, Japan

Site Status

Shimizu Eye Clinic

Musashino, Tokyo, Japan

Site Status

WAKABA Eye Clinic

Ōta-ku, Tokyo, Japan

Site Status

Seijo Clinic

Setagaya City, Tokyo, Japan

Site Status

Yotsuya Shirato Ganka

Shinjuku, Tokyo, Japan

Site Status

Tachihi Bill clinic

Tachikawa, Tokyo, Japan

Site Status

Ueno Eye Clinic

Taito-ku, Tokyo, Japan

Site Status

Hayashi Eye Hospital

Fujuoka, , Japan

Site Status

Hayashi Tennjin Eye Clinic

Fukuoka, , Japan

Site Status

Ohshima Hospital of Opthalmology

Fukuoka, , Japan

Site Status

Kato Eye Clinic

Fukuoka, , Japan

Site Status

Gifu University Hospital

Gifu, , Japan

Site Status

Hiroshima University Hospital

Hiroshima, , Japan

Site Status

Niigata University Medical and Dental Hospital

Niigata, , Japan

Site Status

Nishi Eye Hospital

Osaka, , Japan

Site Status

Adachi Eye Clinic

Osaka, , Japan

Site Status

Osaka Welfare Pension Hospital

Osaka, , Japan

Site Status

Nanba Opthalmology

Shizuoka, , Japan

Site Status

Sugita Eye Hospital

Sugita, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Related Links

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A6641050

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.